Subscribe to our newsletter.
Introducing CBFB-MYH11 Kit
The CBFB-MYH11 Kit is an advanced molecular diagnostic platform designed to facilitate the precise identification and quantification of the CBFB-MYH11 fusion gene, resultant from chromosomal rearrangement inv(16)(p13q22). This genetic aberration is pivotal in the diagnosis and prognosis of Acute Myeloid Leukemia (AML), and the kit aims to provide clinicians and molecular biologists with a robust, reliable method for its detection.
Utilizing sophisticated real-time Polymerase Chain Reaction (PCR) technology, the kit employs a combination of oligonucleotides and hydrolysis probes. It is tailored to amplify and quantify the type A variant of the CBFB-MYH11 fusion gene, accounting for 85% of such occurrences. The kit uses a reference plasmid for calculating the number of copies of the rearrangement and the endogenous gene ABL1, thereby providing a comprehensive analytical output.
Adherence to stringent quality standards ensures that each component of the kit performs optimally. The Limit of Quantification (LoQ) is meticulously calibrated at 125 total copies for both the reference gene ABL1 and the chromosomal rearrangement inv(16)(p13q22), thereby ensuring high fidelity in molecular quantification.
The kit is capable of achieving a theoretical sensitivity level of MR4:0.01%, a critical metric for the detection of Minimal Residual Disease (MRD). It is worth noting that the assay requires 10 µL of cDNA, synthesized by reverse transcription of total RNA extracted from peripheral blood samples.
Five Reasons to Choose This Kit: Unmatched Capabilities
The Final Word: Why This Kit Is a Game-Changer in AML Research
The CBFB-MYH11 Kit is an indomitable tool in the realm of molecular diagnostics for AML, crafted for professionals in the field. Offering unparalleled levels of accuracy, sensitivity, and regulatory compliance, the kit provides a comprehensive suite of capabilities that extend from gene identification to MRD detection. This tool is not merely an addition to the molecular biologist’s repertoire; it sets a new standard for AML diagnostic and prognostic assessment.
The kit contents the necessary reagents to perform 48 reactions. The reagents included in the kit are the following: